Defective Phagocytosis by Human Monocyte/macrophages Following HIV-1 Infection: Underlying Mechanisms and Modulation by Adjunctive Cytokine Therapy
Overview
Authors
Affiliations
Defective immunological function of cells of the macrophage lineage contributes considerably to the pathogenesis of HIV-1 infection. Impairment of phagocytosis of opportunistic pathogens such as Mycobacterium avium complex (MAC), Pneumocystis carinii, Toxoplasma gondii or Candida albicans by peripheral blood monocytes, tissue macrophages and monocyte-derived macrophages following in vivo and in vitro HIV-1 infection is well documented. The development of opportunistic infections due to these pathogens in HIV-infected individuals at late stages of disease is attributed to defective monocyte/macrophage function. The mechanisms whereby HIV-1 impairs phagocytosis are not well known. A number of phagocytic receptors normally mediate engulfment of specific opportunistic pathogens by cells of macrophage lineage; distinct mechanisms are triggered by pathogen-receptor binding to promote cytoskeletal rearrangements and engulfment. This review focuses on the signalling events occurring during Fcgamma receptor- and complement receptor-mediated phagocytosis, and considers the mechanisms by which HIV-1 inhibits those signalling events. Since macrophage function is enhanced by cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-gamma), the use of these immunomodulators is of potential interest as adjunctive immunotherapy in immunosuppressed individuals. In this review we present examples of clinical applications of GM-CSF and IFN-gamma therapy for the treatment of opportunistic infections in HIV-infected individuals receiving antiretroviral drugs.
Monocytes across life span in HIV infection: lights and shadows.
Neri A, Olivieri G, Pighi C, Amodio D, Cotugno N, Palma P Curr Opin HIV AIDS. 2025; 20(2):133-144.
PMID: 39774439 PMC: 11809736. DOI: 10.1097/COH.0000000000000910.
Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies.
Obeagu E, Obeagu G Medicine (Baltimore). 2024; 103(9):e37354.
PMID: 38428854 PMC: 10906605. DOI: 10.1097/MD.0000000000037354.
HIV/Mtb Co-Infection: From the Amplification of Disease Pathogenesis to an "Emerging Syndemic".
Azevedo-Pereira J, Pires D, Calado M, Mandal M, Santos-Costa Q, Anes E Microorganisms. 2023; 11(4).
PMID: 37110276 PMC: 10142195. DOI: 10.3390/microorganisms11040853.
The cytokine/chemokine response in /HIV infection and co-infection.
Maksoud S, Hokayem J Heliyon. 2023; 9(4):e15055.
PMID: 37082641 PMC: 10112040. DOI: 10.1016/j.heliyon.2023.e15055.
Watson Z, Tang S Cells. 2022; 11(12).
PMID: 35741071 PMC: 9222069. DOI: 10.3390/cells11121943.